Actinac

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Actinac

Property Description
Active Ingredient Aceclofenac
Pharmacological Class Non-steroidal Anti-inflammatory Drug (NSAID)
Form Tablet (Film-coated), or Topical Gel
Origin Synthetic (Diclofenac Derivative)
Common Use Symptomatic management of pain and inflammation

Actinac is a synthetic medicinal product defined by its active ingredient, Aceclofenac, a substance formally classified as a Non-steroidal Anti-inflammatory Drug (NSAID). This pharmacological agent belongs to the broader Anti-rheumatic drug group, functioning primarily as a cyclooxygenase inhibitor to provide symptomatic relief. Aceclofenac is chemically a Diclofenac derivative and a Phenylacetic acid derivative, placing it within a well-established class of anti-inflammatory compounds.

Actinac's Identity and Pharmacological Class

The core of Actinac is Aceclofenac, a synthetic compound that primarily acts by limiting the body’s production of chemical messengers known as prostaglandins, which are key mediators of pain and swelling. Actinac is officially classified within the Acetic acid derivatives and related substances class (M01AB16). This categorization confirms its capability to deliver both a direct analgesic effect and a significant anti-inflammatory effect. Aceclofenac is used for symptomatic relief in comparison to certain older-generation NSAIDs.

Composition and Presentation

Actinac is most commonly available as an oral preparation, frequently a film-coated tablet, intended for systemic action following ingestion. The product is typically a single active ingredient product, containing Aceclofenac alongside necessary pharmaceutical excipients (binders and fillers) to ensure the stability and proper function of the solid oral dosage form. The development of Aceclofenac as a Diclofenac derivative represents a specific pharmaceutical effort to create an anti-inflammatory compound for managing chronic discomfort, such as the pain associated with stiff joints in the adult population.

General Therapeutic Purpose and Action

The general purpose of Actinac is to alleviate discomfort and reduce inflammation by inhibiting the process that drives these symptoms. By blocking prostaglandin synthesis, the drug provides symptomatic relief from swelling, pain, and, to a lesser extent, elevated body temperature associated with inflammatory conditions. For instance, it is commonly used to ease the chronic discomfort and swelling experienced in joint conditions.

What side effects are possible with Actinac?

Possible Side Effects and Safety Information

Actinac (Aceclofenac), like other Non-steroidal Anti-inflammatory Drugs (NSAIDs), has an officially documented safety profile characterized by adverse reactions classified by frequency and grouped by System-Organ Class (SOC) based on regulatory documents.

Frequency-Classified Adverse Reactions

The most Common effects, reported in up to 1 in 10 patients, include gastrointestinal issues such as dyspepsia, abdominal pain, nausea, and diarrhea, along with dizziness and increased hepatic enzymes. Uncommon effects may involve flatulence, gastritis, rash, or pruritus. Rare adverse reactions include anaphylactic reaction (shock), hypersensitivity, and cardiac failure.

Serious Adverse Reactions and Systemic Safety

The official labeling identifies several serious, though rare, adverse reactions. These include a risk of Gastrointestinal bleeding, ulceration, or perforation, which can occur at any time during treatment. Severe mucocutaneous skin reactions, such as Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis, are also documented as very rare risks. The drug is associated with potential risks to the cardiovascular system, including the onset of hypertension and cardiac failure.

Population-Specific Safety Considerations

The regulatory profile specifies increased risk for certain patient groups. The elderly are noted to have a higher frequency of serious adverse reactions, particularly GI complications. Caution and monitoring are necessary for patients with renal or hepatic impairment. Furthermore, the use of Actinac is contraindicated during the last trimester of pregnancy and is not recommended for women attempting to conceive.

Overdose and Emergency Response

The official regulatory documentation for Actinac (Aceclofenac), a Non-steroidal Anti-inflammatory Drug, describes specific overdose manifestations and mandates clear emergency actions.

Documented Overdose Presentations

Initial overdose may present with gastrointestinal symptoms such as nausea, vomiting, and abdominal pain, along with Central Nervous System effects including headache, dizziness, lethargy, and somnolence. Officially documented severe outcomes include potentially life-threatening organ injury, specifically acute renal failure, hepatic failure, and major gastrointestinal bleeding or perforation. Other serious complications noted in regulatory documents are convulsions and coma.

Individuals with pre-existing impaired renal, cardiac, or liver function, and the elderly population, are identified as being at increased risk for these severe complications.

When to Seek Immediate Medical Help

Official regulatory statements mandate that patients must seek immediate medical attention for any suspected overdose. Urgent care is specifically required if serious symptoms develop, such as chest pain, trouble breathing, sudden weakness, or slurred speech, as these may indicate severe complications linked to NSAID use.

Official Overdose Management

Management is strictly focused on symptomatic and supportive treatment, as no specific antidote is known to reverse the effects of Aceclofenac overdose. This includes hospital monitoring and the consideration of procedures such as gastric lavage or activated charcoal following recent ingestion.

Therapeutic Uses of Actinac

What Actinac Treats: Main Uses and Benefits

Actinac is applied across specific therapeutic domains to provide essential symptomatic relief, particularly in situations where symptoms related to physical discomfort may interfere with daily functioning. The medication is commonly used to help manage symptoms associated with inflammatory conditions, including Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis, providing relief for pain and inflammation in these chronic joint disorders.

It is also relevant for easing acute and localized painful episodes such as Low Back Pain, Scapulohumeral Periarthritis, and Dysmenorrhea. Actinac is relevant for easing the symptoms related to inflammatory or irritative states, which supports general well-being during symptomatic phases. This symptomatic support is intended to help patients cope more steadily with symptom fluctuations and may assist with maintaining functional stability.

Quick Fact: Managing Symptoms Related to Joint Stiffness

Actinac is commonly used to address the rigid or limited movement, known as morning stiffness, that often accompanies chronic inflammatory joint conditions. This supportive action contributes to easing the overall symptom load and supports general well-being during symptomatic phases.

Regulatory References

  1. Rwanda FDA SmPC document

Eligibility and Restrictions for Use

Who Can and Cannot Use Actinac?

The population eligibility for Actinac (Aceclofenac) is strictly governed by regulatory labeling, which defines both eligible groups and absolute prohibitions.

Absolute Contraindications (Must Not Use)

Use of Actinac is strictly contraindicated in several patient groups, including those with known hypersensitivity to Aceclofenac, aspirin, or other NSAIDs. It must not be used by patients with severe hepatic failure or severe renal failure, or those with a history of active or recurrent gastrointestinal bleeding/ulceration.

Furthermore, Actinac is contraindicated in patients with established cardiovascular disease (such as Congestive Heart Failure, NYHA Class II–IV), and during the third trimester of pregnancy.

Population Restrictions and Conditional Use

Age Group / Condition Regulatory Statement
Pediatric Population (Under 18) Not recommended due to a lack of clinical data.
The Elderly Use requires caution and the lowest effective dose due to increased risk of serious adverse reactions.
Mild to Moderate Organ Impairment Requires close medical surveillance (hepatic) or regular monitoring (renal).
First and Second Trimesters Use should be avoided unless strictly necessary.

Actinac is primarily intended for use in the adult population under standard labeled conditions. Breastfeeding women are generally not recommended to use the medicine.

What should I know about interactions with other medicines?

Actinac's interaction profile is officially defined by specific regulatory constraints concerning co-administration with other medicinal products and substances. Combination with other Non-Steroidal Anti-inflammatory Drugs (NSAIDs), including Aspirin and COX-2 inhibitors, is formally contraindicated due to the enhanced risk of serious adverse gastrointestinal events.

The regulatory documents define several clinically significant interaction categories.

Documented Interaction Outcomes

  • Increased Drug Exposure: Actinac may increase the plasma concentrations of co-administered medicines, including Lithium, Digoxin, and Methotrexate.
  • Haemorrhagic Risk: Co-administration with Anticoagulants (e.g., Warfarin), Antiplatelet Agents, Corticosteroids, or SSRIs may increase the risk of haemorrhage or gastrointestinal ulceration due to additive pharmacodynamic effects.
  • Renal and Efficacy Interference: Actinac can diminish the therapeutic effect of Diuretics and Antihypertensive Agents (ACE Inhibitors, ARBs). Co-administration is formally associated with an increased risk of renal function deterioration (nephrotoxicity), a risk that is also enhanced when combined with Cyclosporine. The risk of renal deterioration is specifically heightened in the elderly and in patients with impaired renal function.
  • Other Interactions: Concomitant use with Quinolone Antibiotics may lead to the precipitation of convulsions.
  • Non-Medicinal Substances: Administration with food is documented to reduce the rate of absorption, but the total extent of absorption remains unchanged. Regular alcohol consumption is officially noted to increase the risk of gastric bleeding.

Mechanism of Action

Targeting the Inflammatory Cascade via Enzyme Inhibition

The primary action of Aceclofenac involves the preferential inhibition of the Cyclooxygenase-2 (COX-2) enzyme, which is responsible for synthesizing inflammatory mediators like Prostaglandins. This selective interference limits the biochemical fuel that drives the inflammatory cascade, leading directly to the physiological consequence of anti-inflammation and reduced local fluid extravasation.


Modulating Nociceptive and Thermoregulatory Signaling

By significantly reducing the level of Prostaglandin E2 (PGE2), the drug modulates the nociceptive signaling pathway in both peripheral nerve endings and central brain centers. This action limits the nervous system's capacity for nociceptor sensitization, resulting in the physiological effect of analgesia. The same central mechanism applied to the hypothalamus supports the physiological effect of antipyresis.


Non-Prostaglandin Effects and Tissue Regulation

Beyond COX inhibition, the drug's mechanism includes the direct suppression of certain pro-inflammatory cytokines (like IL-1beta) and an influence on enzymes that govern connective tissue homeostasis. This more complex mechanism is relevant in systems requiring targeted pathway adjustment and contributes to the modulation of physiological responses in local tissues.

Dosage and Administration Information

The administration of Actinac, which contains the active ingredient aceclofenac, requires adherence to a physician's instructions to ensure safety and effectiveness. This medication is typically indicated for the relief of pain and inflammation associated with conditions such as osteoarthritis and rheumatoid arthritis.

Administration Guidelines

Guideline Instruction
Dosage The standard recommended daily dose of aceclofenac is 200 mg, taken as two separate 100 mg doses: one in the morning and one in the evening.
Method Swallow the tablet whole with a sufficient quantity of liquid. Do not chew, crush, or break the tablet.
With Food It is recommended to take Actinac preferably with or after food. This measure may help reduce the potential for gastrointestinal irritation, a known risk with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).
Duration The lowest effective dose should be used for the shortest duration necessary to control symptoms. Do not exceed the prescribed dose or treatment duration without consulting your healthcare provider.

Important Considerations

Patients should be monitored regularly for signs of gastrointestinal bleeding or other adverse effects, particularly with long-term use. For individuals with liver impairment, a reduced initial daily dose may be suggested. The use of this drug is generally not recommended in children.

Recent Clinical Evidence

Actinac: Recent Clinical Evidence

Evidence in Osteoarthritis

Research has explored whether Actinac is associated with changes in symptoms of osteoarthritis (OA). Studies typically evaluated the drug's use to assess its potential association with reduced self-reported pain and metrics related to functional status in participants with OA. Initial assessments from short-term trials suggested some association with changes in pain metrics across a 12-week period. However, longer-term results were not consistent across all trials, and the evidence base does not currently allow for definitive conclusions on long-term joint damage progression.

Research has also explored whether the use of Actinac in combination with other standard therapies was associated with different outcomes compared to therapies used alone. Furthermore, some studies included quality of life assessments, such as evaluating changes in sleep patterns and mood.


Research into Drug Activity and Safety

Research has examined the drug's properties related to anti-inflammatory activity and whether this was associated with self-reported pain outcomes. The research included investigation into the potential molecular basis of the drug's activity.

Safety data has been collected primarily through short-term randomized controlled trials (RCTs). The most frequently reported adverse events included mild gastrointestinal upset, headache, and fatigue. Reported events were monitored in the context of the study protocols.

Studies also explored the potential for drug-drug interactions when Actinac was used alongside common pain relievers. It is important to note that studies often excluded participants with pre-existing or severe kidney conditions, and the impact of the drug on this specific population is not well-established in the current literature.

Key Studies & References

  1. Efficacy and Safety of Aceclofenac Controlled Release in Patients with Knee Osteoarthritis: A 4-week, Multicenter, Randomized, Comparative Clinical Study (Representative RCT on NSAID efficacy/safety/dosing)
  2. Current Status of Symptomatic Slow-acting Drugs for Osteoarthritis (SYSADOAs) in Spain (Review on long-term effects, uncertainty, and comparisons)
  3. The Impact of Chronic Pain, Stiffness and Difficulties in Performing Daily Activities on the Quality of Life of Older Patients with Knee Osteoarthritis (Observational study on QOL/sleep metrics)

Frequently Asked Questions (FAQ)

Common questions about Actinac (FAQ)


Q: Is Actinac meant to be taken long-term or short-term?

Official product information states that this medication should be used at the lowest effective dose for the shortest duration necessary to control symptoms. This is a general safety measure that applies to this class of anti-inflammatory drugs. Regulatory guidelines do not specify a fixed maximum duration, but emphasize that treatment length is subject to re-evaluation by a healthcare provider.

Q: How quickly does Actinac usually start working for people?

Studies indicate that the active ingredient in Actinac is rapidly absorbed. In clinical trials, significant improvements in symptoms compared to the starting baseline were generally apparent by the time of the first assessment, which was approximately two weeks.

Q: Is Actinac commonly prescribed for conditions other than joint inflammation?

Official indications show Actinac is formally used for the symptomatic management of pain and inflammation associated with joint conditions such as osteoarthritis and rheumatoid arthritis. It is also formally indicated for the relief of symptoms related to ankylosing spondylitis.

Q: How long after stopping Actinac will it stay in my system?

The active ingredient in Actinac, aceclofenac, has a mean plasma elimination half-life of approximately 4 hours. Based on the half-life, the drug's active ingredient is expected to be substantially eliminated from the body within approximately 24 hours when used as prescribed.

Q: Is Actinac safe to use if I have high blood pressure?

Patients with a history of hypertension (high blood pressure) or heart failure require monitoring. The decision to use this medication is made after careful medical consideration and typically involves appropriate patient surveillance, as NSAIDs like Actinac have been associated with a risk of fluid retention and oedema (swelling).

Q: What kind of monitoring is typically required while taking Actinac?

Close medical surveillance is necessary, especially for patients with a history of gastrointestinal disorders or existing kidney (renal) or liver (hepatic) impairment. Monitoring for signs of GI bleeding and checking liver function tests may be required. Furthermore, pre-treatment baseline tests may be necessary for patients with existing risk factors.

Q: Is it normal to have a slight headache when first taking Actinac?

Headache is listed as a common side effect reported for this medication. Any persistent or severe adverse effects, including headaches, should be discussed with the prescribing physician.

Q: What should I do if I notice a rash after starting Actinac?

Official product information indicates the medication should be discontinued immediately at the first sign of a skin rash, mucosal lesions, or any other sign of a hypersensitivity (allergic) reaction. This is due to the documented potential for rare, severe skin reactions associated with this drug class.

Q: Is there an established maximum duration for Actinac treatment?

Regulatory guidelines do not specify a fixed maximum duration for treatment. They state that the medication must be used for the shortest duration necessary to control symptoms, using the lowest effective dose possible.

Q: Can Actinac cause tiredness or difficulty concentrating?

Adverse effects such as drowsiness, dizziness, vertigo, and fatigue are possible after taking this type of medication. If these central nervous system (CNS) effects occur, official information states that activities requiring alertness, such as driving or operating machinery, should be avoided.

Q: Can Actinac cause sensitivity to sunlight?

Skin reaction to sunlight (photosensitivity) has been reported as an adverse effect of this type of medication (NSAIDs). Individuals using this drug may need to be cautious about sun exposure.

Q: Is Actinac associated with weight changes?

Weight gain and fluid retention (oedema) have been reported as adverse reactions in the post-marketing experience for this drug class.

Q: Can Actinac cause changes in mood or sleep?

The central nervous system effects of Actinac are monitored in clinical use. While the most common adverse effects are physical, rare adverse effects reported for this drug class include depression and mental disturbances like confusion or hallucinations.

Q: What happens if I forget to take Actinac one day?

Regulatory guidance for a missed dose recommends skipping the forgotten dose entirely and taking the next dose at the usual time. Official instructions state not to take a double dose.

Q: Is Actinac considered a controlled substance?

No, this medication (Aceclofenac) is classified as a Non-Steroidal Anti-inflammatory Drug (NSAID). According to regulatory classifications, the drug is not listed as a controlled substance by major government authorities.

Q: Can men use Actinac if their partner is trying to conceive?

The official label includes specific warnings regarding its use and effect on female fertility and during pregnancy. However, the regulatory label does not include a specific warning or restriction regarding its use and effects on male fertility.

How should Actinac be stored and disposed of?

How to Store and Dispose of Actinac: Official Instructions

Official regulatory documents define mandatory requirements for the storage, handling, and disposal of Actinac (e.g., ER 200 Tablets) to maintain product quality and safety.


Storage and Handling

The product must be stored at a temperature at or below 30°C and must be kept protected from both heat and moisture. Actinac should be stored in a dry, cool, and well-ventilated location, with the container kept tightly closed. To ensure safety, the medicine must be stored away from children and pets.

️ Disposal Requirements

Unused or expired Actinac and any waste material must be disposed of in accordance with local requirements. It is officially required to prevent the discharge of the product into the environment, including drains. Special precautions for disposal are typically not applicable for this formulation, but local guidelines must be strictly followed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Actinac found in:

A-Z Index: